November 30, 2017 09:49 AM ESTUpdated 10:20 AM
News Briefing

Sen­a­tors grill Alex Azar on drug prices; Mor­phoSys sells rights to Darza­lex ri­val in $120M deal; Se­r­i­al deal­mak­er X-Chem en­ters new dis­cov­ery pact with Gilead

Brittany Meiling

→ Alex Azar faced a group of skep­ti­cal sen­a­tors on Wednes­day, De­moc­rats and Re­pub­li­cans, as they re­viewed his nom­i­na­tion as chief of HHS un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times